

Improving research protections means improving research quality.



Demonstrate your organization's commitment to human research protections through accreditation.

AAHRPP accreditation...

- improves your human research protection program
- assists your organization in achieving regulatory compliance
- helps your organization compete for sponsored research
- "raises the bar" in overall research quality
- builds and enhances public trust


AAHRPP
Association for the Accreditation of
Human Research Protection Programs, Inc.®

For information call
(202)783-1112, www.aahrpp.org

FASEB
AAHRPP Founding Member



HELL IS THE PLACE WHERE NOTHING CONNECTS — T.S. ELIOT




reliable reference linking, powered by CrossRef

Linking to and from this journal is powered by CrossRef.
CrossRef links millions of articles and chapters, from
thousands of publications, from hundreds of publishers.
So your reference linking works. Permanently. Take a
tour at www.crossref.org. And make sure all your
published work is CrossRef-enabled.



CROSSREF.ORG | THE CITATION LINKING BACKBONE

40 SALEM STREET, LYNNFIELD MA 01940 • 781-295-0072



WE ARE PHARMACOLOGISTS

The Federation of American Societies for Experimental Biology is a coalition of life science societies dedicated to enhancing the quality of life through research. If you are a member of the American Society for Pharmacology and Experimental

Therapeutics you—like more than 65,000 other scientists—are a member of FASEB. FASEB strives to provide support in public affairs, distinguished publications, invaluable meetings and conferences, and a variety of member services.

FASEB—we are life scientists and we work for you. www.faseb.org

FASEB



Online Manuscript Submission

for three leading journals in pharmacology

jpet.org ♦ molpharm.org ♦ dmd.org

Washington DC Principles for **FREE ACCESS TO SCIENCE**



The Washington DC Principles is a commitment from 50 (and growing) not-for-profit medical/scientific societies and publishers to provide free access and wide dissemination of published research findings.

The DC Principles provide what has been called the needed “middle ground” in the increasingly heated debate between those who advocate immediate unfettered online access to medical and scientific research findings and advocates of the current journal publishing system. The document was drafted in response to recent claims that these publishers’ practices hinder the public’s ability to access published scientific research.

The 7 Principles

- 1** As not-for-profit publishers, we see it as our mission to maintain and enhance the independence, rigor, trust, and visibility that have established scholarly journals as reliable filters of information emanating from clinical and laboratory research.
- 2** As not-for-profit publishers, we reinvest all of the revenue from our journals in the direct support of science worldwide, including scholarships, scientific meetings, grants, educational outreach, advocacy for research funding, the free dissemination of information for the public, and improvements in scientific publishing.
- 3** As not-for-profit publishers, we have introduced and will continue to support the following forms of free access:
 - a. Selected important articles of interest are free online from the time of publication;
 - b. The full text of our journals is freely available to everyone worldwide either immediately or within months of publication, depending on each publisher’s business and publishing requirements;
 - c. The content of our journals is available free to scientists working in many low-income nations;
 - d. Articles are made available free online through reference linking between these journals;
 - e. Our content is available for indexing by major search engines so that readers worldwide can easily locate information.
- 4** We will continue to work to develop long-term preservation solutions for online journals to ensure the ongoing availability of the scientific literature.
- 5** We will continue to work with authors, peer-reviewers, and editors for the development of robust online and electronic tools to improve efficiency of their important intellectual endeavors.
- 6** We strongly support the principle that publication fees should not be borne solely by researchers and their funding institutions, because the ability to publish in scientific journals should be available equally to all scientists worldwide, no matter what their economic circumstances.
- 7** As not-for-profit publishers, we believe that a free society allows for the co-existence of many publishing models, and we will continue to work closely with our publishing colleagues to set high standards for the scholarly publishing enterprise.

Why Publish with ASPET?

Because ASPET gives you these advantages:

- ◆ **Low Page Charges** — \$35/page for ASPET members, \$70/page for nonmembers (publishing one paper can save the \$125 membership dues)
- ◆ **Low Color Fees** — \$200/color figure for ASPET members, \$400/color figure for nonmembers
- ◆ **Online Manuscript Submission** — submit your manuscript 24/7 — whenever it suits your schedule; online peer review reduces review times; track the progress of your manuscript through the review process
- ◆ **Publish Online Ahead of Print** — manuscripts are published online shortly after acceptance — at least two months prior to print publication
- ◆ **Wide Dissemination** — full-text articles are freely accessible online 12 months after publication; low-cost pay-per-view option for nonsubscribers; abstracts and tables of contents always freely accessible

The Journal of
PHARMACOLOGY
and Experimental Therapeutics

**MOLECULAR
PHARMACOLOGY**

**DRUG METABOLISM
AND DISPOSITION**

Visit www.aspetjournals.org to access each ASPET journal.



ASPET Journals — Widely Read, Highly Respected

2006 Meetings of ISSX

International Society for the Study of Xenobiotics



1st Asian Pacific ISSX Meeting:

Role of Metabolism and Transport in Drug Discovery and Development



Jeju Island, Korea • May 25 – 27, 2006

Abstract deadline: March 15, 2006

Chair of Meeting Organizing Committee:

Chang-Koo Shim, Seoul National University, Korea

English will be the official language for this meeting.

For more information, please contact ysryu@mnckorea.co.kr

9th European ISSX Meeting:

Safe and Effective Medicines in the Genomic Era



Manchester, UK • June 4 – 7, 2006

Abstract deadline: February 3, 2006

Chair of Meeting Organizing Committee:

Kevin Park, University of Liverpool, UK

For more information, please contact nholahan@issx.org

14th North American ISSX Meeting:

From Drug Biotransformation to Future Innovation



Rio Grande, Puerto Rico, USA • October 22 - 26, 2006

Abstract deadline: May 20, 2006

Chair of Meeting Organizing Committee:


J. Steven Leeder, Childrens Mercy Hospital, Kansas City, MO, USA

For more information, please contact nholahan@issx.org

**Abstracts will be published in *Drug Metabolism Reviews*.
Please check www.issx.org for updates**

BD Gentest™ Products and Services

Helping You to the Finish Line



Overcome Your ADME Hurdles



Helping all people
live healthy lives

BD Biosciences, an innovator of reagents and ADME/Tox services, offers a comprehensive line of tools to overcome your discovery and development hurdles.

- **Scientific Excellence**—Innovative products with real-world applications and direct access to industry-leading scientists push you out of the starting block.
- **Breadth of Line**—More than 600 products, custom capabilities, and tailored contract services give you what you need to get running.
- **Quick Turnaround**—Prompt delivery and extended technical service help you pick up speed.
- **Personalized Service**—Technical resources and a highly-trained staff help you win the race.

Put your trust in the brand the world recognizes as a leader in ADME/Tox: BD Gentest™.

Visit us at bdbiosciences.com/ADMETox today, and rest assured you'll clear your next hurdle on the way to the finish line.

BD Biosciences
Two Oak Park
Bedford, MA 01730
bdbiosciences.com